Pictet Asset Management Holding SA Increases Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Pictet Asset Management Holding SA lifted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 9.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 272,704 shares of the company's stock after acquiring an additional 22,414 shares during the quarter. Pictet Asset Management Holding SA owned 0.32% of CRISPR Therapeutics worth $10,734,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in CRSP. ARK Investment Management LLC grew its position in CRISPR Therapeutics by 19.7% during the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company's stock worth $353,180,000 after purchasing an additional 1,474,439 shares during the period. State Street Corp raised its position in CRISPR Therapeutics by 25.0% during the third quarter. State Street Corp now owns 2,992,988 shares of the company's stock valued at $140,611,000 after acquiring an additional 599,304 shares in the last quarter. Norges Bank purchased a new position in CRISPR Therapeutics during the fourth quarter valued at approximately $17,458,000. Contrarius Group Holdings Ltd acquired a new position in CRISPR Therapeutics in the fourth quarter valued at approximately $14,516,000. Finally, Raymond James Financial Inc. purchased a new stake in CRISPR Therapeutics in the 4th quarter worth approximately $3,231,000. Hedge funds and other institutional investors own 69.20% of the company's stock.

Insider Buying and Selling

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of the firm's stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares of the company's stock, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Greene bought 7,000 shares of CRISPR Therapeutics stock in a transaction on Wednesday, February 26th. The stock was acquired at an average price of $44.85 per share, for a total transaction of $313,950.00. Following the transaction, the director now directly owns 7,000 shares of the company's stock, valued at approximately $313,950. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 32,381 shares of company stock worth $1,608,243. Insiders own 4.10% of the company's stock.

Remove Ads

Analyst Ratings Changes

CRSP has been the subject of several analyst reports. Bank of America decreased their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. Cantor Fitzgerald reissued a "neutral" rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Chardan Capital cut their price target on CRISPR Therapeutics from $94.00 to $84.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. Morgan Stanley increased their price target on CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an "underweight" rating in a research report on Friday, February 14th. Finally, Needham & Company LLC restated a "buy" rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $73.11.

CRISPR Therapeutics Stock Performance

Shares of CRSP stock traded down $0.27 during trading hours on Monday, reaching $32.38. The company had a trading volume of 3,719,781 shares, compared to its average volume of 1,586,715. CRISPR Therapeutics AG has a 12-month low of $30.04 and a 12-month high of $67.88. The company has a market capitalization of $2.78 billion, a price-to-earnings ratio of -7.41 and a beta of 1.85. The stock has a fifty day moving average of $41.97 and a 200-day moving average of $44.52.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.